[HTML][HTML] Optimising quality of life for people living with heart failure in care homes: Protocol for the co-design and feasibility testing of a digital intervention
J McMahon, C Brown Wilson, L Hill, P Tierney… - Plos One, 2023 - journals.plos.org
Background Heart failure (HF) affects up to 64.3 million people globally. Advancements in
pharmaceutical, device or surgical therapies, have led to patients living longer with HF …
pharmaceutical, device or surgical therapies, have led to patients living longer with HF …
Optimising quality of life for people living with heart failure in care homes: Protocol for the co-design and feasibility testing of a digital intervention.
J McMahon, C Brown Wilson, L Hill, P Tierney… - PLoS …, 2023 - search.ebscohost.com
Background: Heart failure (HF) affects up to 64.3 million people globally. Advancements in
pharmaceutical, device or surgical therapies, have led to patients living longer with HF …
pharmaceutical, device or surgical therapies, have led to patients living longer with HF …
Optimising quality of life for people living with heart failure in care homes: Protocol for the co-design and feasibility testing of a digital intervention.
J McMahon, L Hill, P Tierney, DR Thompson… - Plos one, 2023 - europepmc.org
Heart failure (HF) affects up to 64.3 million people globally. Advancements in
pharmaceutical, device or surgical therapies, have led to patients living longer with HF …
pharmaceutical, device or surgical therapies, have led to patients living longer with HF …
Optimising quality of life for people living with heart failure in care homes: Protocol for the co-design and feasibility testing of a digital intervention
J McMahon, CB Wilson, L Hill, P Tierney… - PLoS …, 2023 - research.monash.edu
BACKGROUND: Heart failure (HF) affects up to 64.3 million people globally. Advancements
in pharmaceutical, device or surgical therapies, have led to patients living longer with HF …
in pharmaceutical, device or surgical therapies, have led to patients living longer with HF …
[HTML][HTML] Optimising quality of life for people living with heart failure in care homes: Protocol for the co-design and feasibility testing of a digital intervention
J McMahon, CB Wilson, L Hill, P Tierney… - PLOS …, 2023 - ncbi.nlm.nih.gov
Background Heart failure (HF) affects up to 64.3 million people globally. Advancements in
pharmaceutical, device or surgical therapies, have led to patients living longer with HF …
pharmaceutical, device or surgical therapies, have led to patients living longer with HF …
[PDF][PDF] Optimising quality of life for people living with heart failure in care homes: Protocol for the co-design and feasibility testing of a digital intervention
J McMahon, C Brown Wilson, L Hill, P Tierney… - PLoS …, 2023 - pdfs.semanticscholar.org
Background Heart failure (HF) affects up to 64.3 million people globally. Advancements in
pharmaceutical, device or surgical therapies, have led to patients living longer with HF …
pharmaceutical, device or surgical therapies, have led to patients living longer with HF …
[PDF][PDF] Optimising quality of life for people living with heart failure in care homes: Protocol for the co-design and feasibility testing of a digital intervention
J McMahon, C Brown Wilson, L Hill, P Tierney… - PLoS ONE, 2023 - pure.qub.ac.uk
Background Heart failure (HF) affects up to 64.3 million people globally. Advancements in
pharmaceutical, device or surgical therapies, have led to patients living longer with HF …
pharmaceutical, device or surgical therapies, have led to patients living longer with HF …
[PDF][PDF] Optimising quality of life for people living with heart failure in care homes: Protocol for the co-design and feasibility testing of a digital intervention
J McMahon, C Brown Wilson, L Hill, P Tierney… - PLoS …, 2023 - pureadmin.qub.ac.uk
Background Heart failure (HF) affects up to 64.3 million people globally. Advancements in
pharmaceutical, device or surgical therapies, have led to patients living longer with HF …
pharmaceutical, device or surgical therapies, have led to patients living longer with HF …
Optimising quality of life for people living with heart failure in care homes: Protocol for the co-design and feasibility testing of a digital intervention
J McMahon, CB Wilson, L Hill, P Tierney… - PloS …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Heart failure (HF) affects up to 64.3 million people globally. Advancements in
pharmaceutical, device or surgical therapies, have led to patients living longer with HF …
pharmaceutical, device or surgical therapies, have led to patients living longer with HF …
Optimising quality of life for people living with heart failure in care homes: Protocol for the co-design and feasibility testing of a digital intervention
J McMahon, CB Wilson, L Hill, P Tierney… - PLOS …, 2023 - cris.maastrichtuniversity.nl
Background Heart failure (HF) affects up to 64.3 million people globally. Advancements in
pharmaceutical, device or surgical therapies, have led to patients living longer with HF …
pharmaceutical, device or surgical therapies, have led to patients living longer with HF …